Advertisement

Breast Cancer Research and Treatment

, Volume 135, Issue 3, pp 663–680 | Cite as

Body composition changes in females treated for breast cancer: a review of the evidence

  • Patricia M. Sheean
  • Kent Hoskins
  • Melinda Stolley
Review

Abstract

Body composition changes cannot be precisely captured using body weight or body mass index measures. Therefore, the primary purpose of this review was to characterize the patterns of body composition change in females treated for breast cancer including only studies that utilize imaging technologies to quantify adipose tissue and lean body mass (LBM). We reviewed PubMed for studies published between 1971 and 2012 involving females diagnosed with breast cancer where computed axial tomography , dual-energy X-ray absorptiometry, or magnetic resonance imaging were employed for body composition assessment. Of the initial 440 studies, 106 papers were evaluated and 36 papers met all eligibility criteria (15 observational and 21 intervention trials). Results of these studies revealed that body weight did not consistently increase. Importantly, studies also showed that body weight did not accurately depict changes in lean or adipose tissues. Further findings included that sarcopenic obesity as a consequence of breast cancer treatment was not definitive, as menopausal status may be a substantial moderator of body composition. Overall, the behavioral interventions did not exhibit consistent or profound effects on body composition outcomes; approximately half showed favorable influence on adiposity while the effects on LBM were not apparent. The use of tamoxifen had a clear negative impact on body composition. The majority of studies were conducted in predominantly white survivors, highlighting the need for trials in minority populations. Collectively, these studies were limited by age, race, and/or menopause status matched control groups, overall size, and statistical power. Very few studies simultaneously collected diet and exercise data—two potential factors that impact body composition. Future breast cancer trials should prioritize precise body composition methodologies to elucidate how these changes impact recurrence, prognosis, and mortality, and to provide clinicians with appropriate advice regarding lifestyle recommendations in this growing sector of the population.

Keywords

Breast cancer Body composition Adiposity Lean body mass Breast cancer treatment Imaging 

Notes

Acknowledgments

Support for this study was provided by the National Cancer Institute, Career Education and Career Development Program, #R25CA057699-18.

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    American Cancer Society. http://www.cancer.org
  2. 2.
  3. 3.
    Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Dietetic Assoc, 97(5):519–526, 529 (quiz 527–518)Google Scholar
  4. 4.
    Demark-Wahnefried W, Winer EP, Rimer BK (1993) Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 11(7):1418–1429PubMedGoogle Scholar
  5. 5.
    Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5):491–497PubMedCrossRefGoogle Scholar
  6. 6.
    Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8(8):1327–1334PubMedGoogle Scholar
  7. 7.
    Chlebowski RT, Weiner JM, Reynolds R, Luce J, Bulcavage L, Bateman JR (1986) Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat 7(1):23–30PubMedCrossRefGoogle Scholar
  8. 8.
    Gillum RF, Sempos CT (2005) Ethnic variation in validity of classification of overweight and obesity using self-reported weight and height in American women and men: the Third National Health and Nutrition Examination Survey. Nutr J 4:27PubMedCrossRefGoogle Scholar
  9. 9.
    Cheney CL, Mahloch J, Freeny P (1997) Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer. Am J Clin Nutr 66(1):141–146PubMedGoogle Scholar
  10. 10.
    Demark-Wahnefried W, Hars V, Conaway MR, Havlin K, Rimer BK, McElveen G, Winer EP (1997) Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr 65(5):1495–1501PubMedGoogle Scholar
  11. 11.
    Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19(9):2381–2389PubMedGoogle Scholar
  12. 12.
    Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA (1999) Changes in body composition during breast cancer chemotherapy with the CMF-regimen. Breast Cancer Res Treat 57(3):285–290PubMedCrossRefGoogle Scholar
  13. 13.
    Rose DP, Haffner SM, Baillargeon J (2007) Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev 28(7):763–777PubMedCrossRefGoogle Scholar
  14. 14.
    McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, Gilliland F, Stanczyk FZ, Yasui Y, Ballard-Barbash R (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21(10):1961–1966PubMedCrossRefGoogle Scholar
  15. 15.
    Thomson CA, Thompson PA, Wright-Bea J, Nardi E, Frey GR, Stopeck A (2009) Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Womens Health (Larchmt) 18(12):2041–2047CrossRefGoogle Scholar
  16. 16.
    Medicine ACoS (ed) (2007) ACSM’s Health-Related Physical Fitness Assessment Manual. Williams & Wilkins, LippincottGoogle Scholar
  17. 17.
    Ali PA, al-Ghorabie FH, Evans CJ, el-Sharkawi AM, Hancock DA (1998) Body composition measurements using DXA and other techniques in tamoxifen-treated patients. Appl Radiat Isot 49(5–6):643–645PubMedCrossRefGoogle Scholar
  18. 18.
    Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG (2001) Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 25(2):296–298PubMedCrossRefGoogle Scholar
  19. 19.
    Campbell KL, Lane K, Martin AD, Gelmon KA, McKenzie DC (2007) Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer. Cancer Nurs 30(2):95–100PubMedCrossRefGoogle Scholar
  20. 20.
    Freedman RJ, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, Sebring N, Reynolds JC, Yanovski JA (2004) Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab 89(5):2248–2253PubMedCrossRefGoogle Scholar
  21. 21.
    Gordon AM, Hurwitz S, Shapiro CL, LeBoff MS (2011) Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer. Menopause 18(11):1244–1248PubMedCrossRefGoogle Scholar
  22. 22.
    Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782PubMedCrossRefGoogle Scholar
  23. 23.
    Kutynec CL, McCargar L, Barr SI, Hislop TG (1999) Energy balance in women with breast cancer during adjuvant treatment. J Am Diet Assoc 99(10):1222–1227PubMedCrossRefGoogle Scholar
  24. 24.
    Nissen MJ, Shapiro A, Swenson KK (2011) Changes in weight and body composition in women receiving chemotherapy for breast cancer. Clin Breast Cancer 11(1):52–60PubMedGoogle Scholar
  25. 25.
    Winters-Stone KM, Nail L, Bennett JA, Schwartz A (2009) Bone health and falls: fracture risk in breast cancer survivors with chemotherapy-induced amenorrhea. Oncol Nurs Forum 36(3):315–325PubMedCrossRefGoogle Scholar
  26. 26.
    Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K et al (2008) Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial. Cancer 112(8):1845–1853PubMedCrossRefGoogle Scholar
  27. 27.
    Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K et al (2007) Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25(28):4396–4404PubMedCrossRefGoogle Scholar
  28. 28.
    Demark-Wahnefried W, Case LD, Blackwell K, Marcom PK, Kraus W, Aziz N, Snyder DC, Giguere JK, Shaw E (2008) Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. Clin Breast Cancer 8(1):70–79PubMedCrossRefGoogle Scholar
  29. 29.
    Demark-Wahnefried W, Kenyon AJ, Eberle P, Skye A, Kraus WE (2002) Preventing sarcopenic obesity among breast cancer patients who receive adjuvant chemotherapy: results of a feasibility study. Clin Exerc Physiol 4(1):44–49PubMedGoogle Scholar
  30. 30.
    DeNysschen CA, Brown JK, Cho MH, Dodd MJ (2011) Nutritional symptom and body composition outcomes of aerobic exercise in women with breast cancer. Clin Nurs Res 20(1):29–46PubMedCrossRefGoogle Scholar
  31. 31.
    Djuric Z, Ellsworth JS, Weldon AL, Ren J, Richardson CR, Resnicow K, Newman LA, Hayes DF, Sen A (2011) A diet and exercise intervention during chemotherapy for breast cancer. Open Obes J 3:87–97PubMedCrossRefGoogle Scholar
  32. 32.
    Matthews CE, Wilcox S, Hanby CL, Der Ananian C, Heiney SP, Gebretsadik T, Shintani A (2007) Evaluation of a 12-week home-based walking intervention for breast cancer survivors. Support Care Cancer 15(2):203–211PubMedCrossRefGoogle Scholar
  33. 33.
    Irwin ML, Alvarez-Reeves M, Cadmus L, Mierzejewski E, Mayne ST, Yu H, Chung GG, Jones B, Knobf MT, DiPietro L (2009) Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring) 17(8):1534–1541CrossRefGoogle Scholar
  34. 34.
    Knobf MT, Insogna K, DiPietro L, Fennie C, Thompson AS (2008) An aerobic weight-loaded pilot exercise intervention for breast cancer survivors: bone remodeling and body composition outcomes. Biol Res Nurs 10(1):34–43PubMedCrossRefGoogle Scholar
  35. 35.
    Mefferd K, Nichols JF, Pakiz B, Rock CL (2007) A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors. Breast Cancer Res Treat 104(2):145–152PubMedCrossRefGoogle Scholar
  36. 36.
    Pakiz B, Flatt SW, Bardwell WA, Rock CL, Mills PJ (2011) Effects of a weight loss intervention on body mass, fitness, and inflammatory biomarkers in overweight or obese breast cancer survivors. Int J Behav Med 18(4):333–341Google Scholar
  37. 37.
    Rogers LQ, Hopkins-Price P, Vicari S, Markwell S, Pamenter R, Courneya KS, Hoelzer K, Naritoku C, Edson B, Jones L et al (2009) Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects. Cancer Epidemiol Biomarkers Prev 18(5):1410–1418PubMedCrossRefGoogle Scholar
  38. 38.
    Rogers LQ, Hopkins-Price P, Vicari S, Pamenter R, Courneya KS, Markwell S, Verhulst S, Hoelzer K, Naritoku C, Jones L et al (2009) A randomized trial to increase physical activity in breast cancer survivors. Med Sci Sports Exerc 41(4):935–946PubMedCrossRefGoogle Scholar
  39. 39.
    Schmitz KH, Ahmed RL, Hannan PJ, Yee D (2005) Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 14(7):1672–1680PubMedCrossRefGoogle Scholar
  40. 40.
    Stendell-Hollis NR, Thomson CA, Thompson PA, Bea JW, Cussler EC, Hakim IA (2010) Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors. J Hum Nutr Diet 23(6):590–600PubMedCrossRefGoogle Scholar
  41. 41.
    Thomson CA, Stopeck AT, Bea JW, Cussler E, Nardi E, Frey G, Thompson PA (2010) Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. Nutr Cancer 62(8):1142–1152PubMedCrossRefGoogle Scholar
  42. 42.
    Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A, Schwartz A (2011) Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res Treat 127(2):447–456PubMedCrossRefGoogle Scholar
  43. 43.
    Campbell KL, Van Patten CL, Neil SE, Kirkham AA, Gotay CC, Gelmon KA, McKenzie DC (2012) Feasibility of a lifestyle intervention on body weight and serum biomarkers in breast cancer survivors with overweight and obesity. J Acad Nutr Diet 112(4):559–567PubMedCrossRefGoogle Scholar
  44. 44.
    Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95(2):153–158PubMedCrossRefGoogle Scholar
  45. 45.
    Montagnani A, Gonnelli S, Cadirni A, Caffarelli C, Del Santo K, Pieropan C, Campagna MS, Montomoli M, Petrioli R, Nuti R (2008) The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med 19(8):592–597PubMedCrossRefGoogle Scholar
  46. 46.
    van Londen GJ, Perera S, Vujevich K, Rastogi P, Lembersky B, Brufsky A, Vogel V, Greenspan SL (2011) The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. Breast Cancer Res Treat 125(2):441–446PubMedCrossRefGoogle Scholar
  47. 47.
    Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67(1):93–101PubMedCrossRefGoogle Scholar
  48. 48.
    Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920–2926PubMedCrossRefGoogle Scholar
  49. 49.
    Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282–294PubMedCrossRefGoogle Scholar
  50. 50.
    Rock CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20(15):3302–3316PubMedCrossRefGoogle Scholar
  51. 51.
    Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD (2008) Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 26(20):3310–3316PubMedCrossRefGoogle Scholar
  52. 52.
    Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M (2008) Prognostic value of body mass index in locally advanced breast cancer. Clin Cancer Res 14(6):1718–1725PubMedCrossRefGoogle Scholar
  53. 53.
    de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119(1):145–153PubMedCrossRefGoogle Scholar
  54. 54.
    Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476PubMedCrossRefGoogle Scholar
  55. 55.
    Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97(3):245–254PubMedCrossRefGoogle Scholar
  56. 56.
    Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378PubMedCrossRefGoogle Scholar
  57. 57.
    Majed B, Moreau T, Asselain B (2009) Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points. Breast Cancer Res Treat 115(1):193–203PubMedCrossRefGoogle Scholar
  58. 58.
    Grant B, Bloch AS, Hamilton KK, Thompson CA (2010) American Cancer Society Complete Guide to Nutrition for Cancer Survivors: eating well, staying well during and after cancer. American Cancer Society, Atlanta, Georgia Google Scholar
  59. 59.
    Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9(7):629–635PubMedCrossRefGoogle Scholar
  60. 60.
    Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15(22):6973–6979PubMedCrossRefGoogle Scholar
  61. 61.
    Wang Q, Hassager C, Ravn P, Wang S, Christiansen C (1994) Total and regional body-composition changes in early postmenopausal women: age-related or menopause-related? Am J Clin Nutr 60(6):843–848PubMedGoogle Scholar
  62. 62.
    Aloia JF, McGowan DM, Vaswani AN, Ross P, Cohn SH (1991) Relationship of menopause to skeletal and muscle mass. Am J Clin Nutr 53(6):1378–1383PubMedGoogle Scholar
  63. 63.
    Walshe JM, Denduluri N, Swain SM (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24(36):5769–5779PubMedCrossRefGoogle Scholar
  64. 64.
    http://www.seer.cancer.gov/. Accessed 15 March 2012
  65. 65.
    Foster-Schubert KE, Alfano CM, Duggan CR, Xiao L, Campbell KL, Kong A, Bain CE, Wang CY, Blackburn GL, McTiernan A (2012) Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity (Silver Spring) 20(8):1628–1638Google Scholar
  66. 66.
    Witham MD, Avenell A (2010) Interventions to achieve long-term weight loss in obese older people: a systematic review and meta-analysis. Age Ageing 39(2):176–184PubMedCrossRefGoogle Scholar
  67. 67.
    Kumar NB, Allen K, Cantor A, Cox CE, Greenberg H, Shah S, Lyman GH (1997) Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat 44(2):135–143PubMedCrossRefGoogle Scholar
  68. 68.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R et al (2009) The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat 116(3):521–527PubMedCrossRefGoogle Scholar
  69. 69.
    McCullough ML, Feigelson HS, Diver WR, Patel AV, Thun MJ, Calle EE (2005) Risk factors for fatal breast cancer in African-American women and white women in a large US prospective cohort. Am J Epidemiol 162(8):734–742PubMedCrossRefGoogle Scholar
  70. 70.
    Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294(14):1765–1772PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Patricia M. Sheean
    • 1
  • Kent Hoskins
    • 1
  • Melinda Stolley
    • 2
  1. 1.Institute for Health Research and PolicyUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Department of Medicine, Section for Health PromotionUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations